TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03112070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water aerobic exercise session (WATER)
Description: A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
Study: NCT01710397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid ART initiation
Description: Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
Study: NCT04870268

Intervention type: PROCEDURE
Intervention: endoscopic approach

Intervention type: PROCEDURE
Intervention: surgical internal derivation of WON

Intervention type: PROCEDURE
Intervention: surgical necrosectomy
Study: NCT01023958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727, IV infusion
Description: phase II
Study: NCT04594044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tics training including habit reversal training and exposure response prevention
Description: In an open randomized controlled study, youth were randomized to either individualized, or group treatment. Both therapies included nine sessions, and the parents were offered one group-session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tics training including habit reversal training and exposure response prevention
Description: In an open randomized controlled study, youth were randomized to either individualized, or group treatment. Both therapies included nine sessions, and the parents were offered one group-session.
Study: NCT01457898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPAP II®
Description: VPAP group:inspiratory pressure to generate 6ml/kg of weight and expiratory pressure of 7cmH2O plus oxygen therapy (FIO2=40%) during three hours.
Study: NCT01518959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 180.000 IU monthly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oleum neutralicum
Description: Placebo comparator, 9 ml monthly
Study: NCT03524196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manage Your Life Online (MYLO)
Description: Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage.
Study: NCT04243551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latiglutenase
Description: Administered orally (daily)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally (daily)
Study: NCT00108251

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone
Description: aldosterone receptor blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study: NCT02834338

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: activity tracking for autofeedback
Description: The intervention group receives an unblinded wristband. The handling of the activity trackers is explained to the patients and a predefined mobilization end-point (step-count) for the first five PODs is targeted. The target step-count was set at the 85% quartile obtained from a previous pilot study. The patients are assessed and monitored two times daily between 9 and 11 o'clock AM and between 3 and 5 o'clock PM by a surgical fellow or a study nurse throughout their hospital stay for read-out of the step count, assurance of the proper use and functioning, and for communication of the autofeedback.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: activity tracking for autofeedback
Description: The intervention group receives an unblinded wristband. The handling of the activity trackers is explained to the patients and a predefined mobilization end-point (step-count) for the first five PODs is targeted. The target step-count was set at the 85% quartile obtained from a previous pilot study. The patients are assessed and monitored two times daily between 9 and 11 o'clock AM and between 3 and 5 o'clock PM by a surgical fellow or a study nurse throughout their hospital stay for read-out of the step count, assurance of the proper use and functioning, and for communication of the autofeedback.
Study: NCT01264432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo LDFWAR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT06515938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20μg Engerix-B hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20μg Kangtai hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60μg Kangtai hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 20μg CHO
Study: NCT00738634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-motivated physical activity
Description: Components:~1. Physical activity education in the form of a brief booklet (double sided A4 page).~2. Physical activity motivation tips (one sided A4 page).~3. Pedometer~4. Monitoring chart~5. Online presentation of common obstacles and ways to overcome these obstacles

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: Components:~1. Nutrition education booklet (Double-sided A4 page)~2. Nutrition motivation tips (single-sided A4 page)~3. Nutrition monitoring chart~4. Online presentation of common obstacles and ways to overcome these obstacles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity researcher contact
Description: Behavioral: Self-motivated physical activity~Components:~1. Physical activity education in the form of a brief booklet (double sided A4 page).~2. Physical activity motivation tips (one sided A4 page).~3. Pedometer~4. Monitoring chart~5. Online presentation of common obstacles and ways to overcome these obstacles
Study: NCT02777905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Study: NCT03194009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The patient will received metformin 1 tablet of 850mg every 12 hrs besides lifestyle modification recommendations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: The patient will received recommendations to modify their diet and increase their physical activity every three months towards prevention of diabetes
Study: NCT02092454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzocaine
Description: topical otic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical otic solution
Study: NCT03610074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint Ice Cube
Description: Application in patient's mouth of 3 mint ice cubes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Additional blood test 5 min after mint ice cubes application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient's questioning
Description: Patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application
Study: NCT04016142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin-Paclitaxel adjuvant chemotherapy
Description: Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)
Study: NCT02197585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal mesh hernioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal mesh hernioplasty
Study: NCT03878823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-209
Description: co-administered with glucocorticoid and mineralocorticoid, orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-209
Description: co-administered with glucocorticoid and mineralocorticoid, orally daily
Study: NCT02651844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).~Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file.
Study: NCT02674724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gym Group
Description: Patients from Gym Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period.~The initial load is established as 60% of one-repetition maximum strength test (1RM) applied for each exercise at the beginning of program. Patients will be encouraged to perform 3 sets of 8 to 12 repetitions. All subjects will be instructed to rest for 30-60 second intervals between sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Weights Group
Description: Patients from Free Weights Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period. The program aim to recruit the same muscles requested in Gym Group. Investigators will apply six different exercises with patients lying supine,standing in stance, sitting and in four points kneeling. All exercises aim to strengthen abdominal muscles, trunk extensors, gluteus, quadriceps and scapula adductors. Patients will perform 3 sets of 8 to 12 repetitions, the load will be offered with dumbbells, elastics with different resistances and anklets.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: All three groups will be instructed to perform stretching exercises of trunk, leg and shoulder muscles, according to an illustrated booklet. Only the Control Group patients will be instructed to perform stretching exercises at home in the same 12-week period.
Study: NCT03943914

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Preventive strategy
Description: In the experimental strategy, NIV is performed after inclusion in patients with moderate hypoxemia, defined by a PaO2/FiO2 ratio \< 300 mmHg. The minimally required duration of NIV was 4 hours per day for at least 2 calendar days. The daily duration of NIV can be increased at the discretion of the physician in patients with signs of delayed respiratory failure under HFNC-O2 and improving under NIV. Beyond the first 48 hours, NIV and HFNC-O2 can be stopped and the patient switched to COT if respiratory rate \< 25/min and SpO2 \> 92% under FiO2 \< 30% for at least 6 hours.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: In the control group, patients receive oxygen from nasal cannula or high concentration oxygen mask according to the FiO2 needed to achieve SpO2 \> 92%. NIV is initiated only in patients having PaO2/FiO2 ratio \< 200 mmHg under COT. A trial of curative NIV is allowed at the discretion of the physician in patients who have signs of delayed respiratory failure and no other organ dysfunction. The non-improvement of respiratory conditions after 1 hour of NIV, the NIV-dependence (≥ 12 consecutive hours) or NIV-intolerance should be considered as criteria for endotracheal intubation.
Study: NCT04019717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Inhibitor of HCV nonstructural protein 5A (NS5A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Inhibitor of HCV nonstructural protein 5A (NS5A)
Study: NCT00510341

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Management in Pediatrics (CMP) Program
Description: Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
Study: NCT03746834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NASHA/Dx (Solesta®)
Description: Perianal submucosal injection of 3-4 ml of NASHA/Dx
Study: NCT03646968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib and Docetaxel
Description: Patients who was Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer recieved the treatment of Anlotinib and Docetaxel (Anlotinib, 12mg, po,qd and Docetaxel 175mg/m2, ivgtt, every 21day)
Study: NCT03246022

Intervention type: OTHER
Intervention: continuous positive airway pressure
Description: Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.

Intervention type: OTHER
Intervention: continuous positive airway pressure
Description: Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
Study: NCT00166868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus (Lcr35)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Study: NCT01497548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given on morning (0800) and noon (1200)daily
Study: NCT01162889

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC Injection
Description: Single injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-107 (PF-05230900) SC Injection
Description: Single intravenous infusion, 60 minute duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-107 (PF-05230900) SC Injection
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-107 (PF-05230900) SC Injection
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-107 (PF-05230900) SC Injection
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-107 (PF-05230900) SC Injection
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-107 (PF-05230900) IV Infusion
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-107 (PF-05230900) IV Infusion
Description: Single intravenous infusion, 60 minute duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-107 (PF-05230900) IV Infusion
Description: Single intravenous infusion, 60 minute duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV Infusion
Description: Single intravenous infusion, 60 minute duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-107 (PF-05230900) IV Infusion
Description: Single intravenous infusion, 60 minute duration
Study: NCT03235466

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice Therapy
Description: See Arm 1 \& 2

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice Therapy and Heart Rate Variability Biofeedback
Description: See Arm 2 \& 3

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Rate Variability Biofeedback
Description: See Arm 2 \& 3
Study: NCT02381678

Intervention type: DEVICE
Intervention: Perimount 2900/6900 Heart Valve
Description: This is a retrospective study which ask the subjects implanted with Perimount Heart Valve during 2001 to 2007 back hospital for follow up visit.
Study: NCT05765357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab for injection
Description: Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
Study: NCT01407991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enteral tube placement accuracy
Description: The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NEM method for NG/OG tube placement
Description: measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length
Study: NCT03175926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo Diskus®
Description: device will be given daily for one week, two puffs per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo Diskus®
Description: device will be given daily for one week, two puffs per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo Diskus®
Description: device will be given daily for one week, two puffs per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo Ellipta®
Description: device will be given daily for one week, one puff per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo Ellipta®
Description: device will be given daily for one week, one puff per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo Ellipta®
Description: device will be given daily for one week, one puff per day
Study: NCT04053062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIGHT-PSMA-CART cells
Description: LIGHT-PSMA-CART cells will be given IV at split doses
Study: NCT03519204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLBELLA® XC with Lidocaine
Description: JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips.
Study: NCT03175926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmicort® Turbuhaler®
Description: device will be given daily for one week, two puffs per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmicort® Turbuhaler®
Description: device will be given daily for one week, two puffs per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmicort® Turbuhaler®
Description: device will be given daily for one week, two puffs per day
Study: NCT03409536

Intervention type: DEVICE
Intervention: SSEP monitoring
Description: Participants will be monitored using the SSEP device both before and after induction of a brachial plexus block.
Study: NCT00411450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.